Atlas Venture
Premier early-stage biotech venture capital firm focused on company creation. One of the most experienced biotech VCs with over 40 years of track record, known for building companies from scientific ideas to clinical success.
Website
https://www.atlasventure.comLocation
Cambridge, USA
Founded
1980
AUM
$2B+
Investment Range
$5M - $50M
Portfolio Companies
1
Focus
biotech-focused
Fund Stages
seed, series-a, series-b
Investment Thesis
Atlas Venture focuses exclusively on biotechnology company creation, working with scientists to build companies from the earliest stages. They take a thesis-driven approach, identifying breakthrough science and building leadership teams to translate discoveries into transformative medicines.
Team
Partners / Managing Directors (Health & Bio Focus)
- Bruce Booth, PhD - Partner
- Kevin Bitterman, PhD - Partner
- Jean-François Formela, MD - Partner
- Michael Gladstone - Partner
- David Grayzel, MD - Partner
- Jason Rhodes, PhD - Partner
Other Key Team Members
- Company creation team with deep drug development expertise
Focus Areas
- Biotechnology
- Therapeutics
- Oncology
- Immunology
- Genetic Medicines
- Rare Diseases
- Company Creation
Notable Exits
- Intellia Therapeutics - IPO (2016, NASDAQ: NTLA) - CRISPR/Cas9 pioneer
- Nimbus Therapeutics - Sale of assets to Gilead ($400M+)
- Synlogic - IPO (2017, NASDAQ: SYBX)
- Bluebird Bio - IPO (2013, NASDAQ: BLUE)
- Agios Pharmaceuticals - IPO (2013, NASDAQ: AGIO)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Intellia Therapeutics | Cambridge, Massachusetts, USA | 2014 | therapeuticsbiotech+3 |